自己株式の売却による収入、研究開発費 - 医薬、Transfer To Capital Surplus From Retained EarningsSE他2件
- 【期間】
| 年度 | 自己株式の売却による収入 | 研究開発費 - 医薬 | Transfer To Capital Surplus From Retained EarningsSE | | 利益剰余金（IFRS） |
|---|
| 2007/12 | - | | - | | - | | - | | - | |
| 2008/12 | 667百万 | | - | | - | | - | | - | |
| 2009/12 | 243百万 | -63.6% | - | | - | | - | | - | |
| 2010/12 | 156百万 | -35.8% | - | | - | | - | | - | |
| 2011/12 | 244百万 | +56.4% | - | | - | | - | | - | |
| 2012/12 | 75百万 | -69.3% | - | | - | | - | | - | |
| 2013/12 | 25百万 | -66.7% | - | | - | | - | | - | |
| 2014/12 | - | | - | | - | | -2681億 | | - | |
| 2015/12 | - | | - | | - | | - | | - | |
| 2016/12 | - | | - | | - | | - | | - | |
| 2017/12 | - | | - | | - | | - | | - | |
| 2018/12 | - | | - | | - | | - | | 0.93兆 | |
| 2019/12 | - | | 532億 | | - | | - | | 0.96兆 | +2.7% |
| 2020/12 | - | | 520億 | -2.3% | - | | - | | 0.98兆 | +2.4% |
| 2021/12 | - | | 574億 | +10.4% | - | | - | | 1兆 | +1.8% |
| 2022/12 | - | | 624億 | +8.7% | - | | - | | 1.06兆 | +6.6% |
| 2023/12 | - | | 718億 | +15.1% | - | | - | | 1.13兆 | +6.1% |
